Karyopharm Raises $30 Million in RA Capital Private Placement

Overview

• Karyopharm, which announced the financing Tuesday, expects about $30 million in gross proceeds with the runway projected into late Q3 2026 and up to roughly $44 million more if certain warrants are exercised.
• The package includes 1,030,354 common shares at $6.785 and 3,391,164 pre-funded warrants priced similarly that carry a $0.0001 exercise price, allow immediate conversion, and can quickly lift the share count.
• Accompanying warrants cover 4,421,518 shares at a $10 exercise price and expire 30 days after the company discloses topline results from the Phase 3 XPORT-EC-042 selinexor trial in endometrial cancer.
• The deal was priced at-the-market under Nasdaq rules and is slated to close March 26, with Jefferies and Piper Sandler as placement agents and the unregistered securities sold under federal exemptions.
• Following Tuesday’s news, the stock fell 12.71% to $6.66 in regular trading and reached $6.11 pre-market as market outlets highlighted investor concern about dilution from the warrant-heavy structure.